AA
CASC

ALPS Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

ALPS Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-56,018
Closed -$207K – 1043
2017
Q4 		$207K Buy
+56,018
New +$229K ﹤0.01% 818

ALPS Advisors's CASC Position: Q1 2018 in Review

ALPS Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 56,018 shares — an estimated $207K sold.

ALPS Advisors first reported a position in CASC in Q4 2017 and held it in 1 quarter. The position peaked at $207K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • ALPS Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • ALPS Advisors sold 56,018 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $207K.
  • ALPS Advisors first reported a position in Cascadian Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • ALPS Advisors's Cascadian Therapeutics, Inc. position peaked at $207K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on ALPS Advisors's 13F filing for Q1 2018, filed 1 May 2018.